TK
TKDA.STU Takeda Pharmaceutical Company Limited
- Market cap
- EUR 38.7B
- P/E
- 305.0x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2023.
Is TKDA.STU undervalued?
Graham numberThe Graham number of Takeda Pharmaceutical Company Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Takeda Pharmaceutical Company Limited fundamental analysis
No fundamental analysis for Takeda Pharmaceutical Company Limited yet.
Takeda Pharmaceutical Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi,…
Full company profileTakeda Pharmaceutical Company Limited financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Takeda Pharmaceutical Company Limited annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Cash Flow | |||||||
| Operating Cash Flow | 378B | 328B | 670B | 1.01T | 1.12T | - | - |
| Capital Expenditure | 67.0B | 77.7B | 127B | 111B | 123B | 0.00 | 0.00 |
What these items mean
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
Takeda Pharmaceutical Company Limited dividends
Takeda Pharmaceutical Company Limited has not paid dividends in the last 8 fiscal years.
Who owns Takeda Pharmaceutical Company Limited
- Insiders 0.08%
- Institutions 3.32%
- Public & others 96.61%
- Shares outstanding 784M
- Free float 3.19B
Takeda Pharmaceutical Company Limited company profile
- Company name
- Takeda Pharmaceutical Company Limited
- Ticker
- TKDA.STU
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 49,281
- Fiscal year end
- March
- Address
- 1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan, 103-8668
- Phone
- 81 3 3278 2111
- Website
- takeda.com
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Takeda Pharmaceutical Company Limited management
10- Mr. Milano FurutaCFO & Director · born 1978
- Dr. Andrew S. Plump M.D., Ph.D.President of Research & Development and Representative Director · born 1965
- Ms. Julie KimCEO, President & Director · born 1970
- Dr. Seigo IzumoChair of Management Board
- Mr. Haruhiko HirateMember of Management Board · born 1957
- Mr. Salvatore Alesci M.D., Ph.D.Member of Management Board and Head of R&D Global Science & Biomedical Policy · born 1975
- Michael FoxChief Operating Officer
- Norimasa TakedaChief Accounting Officer & Corporate Controller
- Mr. Iwaaki TaniguchiSenior Vice President of Corporate Finance & Controlling Department
- Mr. Gabriele RicciChief Data & Technology Officer · born 1978